Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 100%High 0 · 0%

Benralizumab 100 mg vs placebo

Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Rate ratio 0.94 [0.85, 1.03]
3 studies · 2314 participants
Moderate

Benralizumab 10 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Rate ratio 0.85 [0.71, 1.02]
1 study · 765 participants
Moderate

Benralizumab 10 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Rate ratio 1.04 [0.82, 1.32]
1 study · 365 participants
Moderate

Benralizumab 30 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Rate ratio 1 [0.89, 1.13]
2 studies · 1523 participants
Moderate

Benralizumab 30 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Rate ratio 1.07 [0.91, 1.27]
2 studies · 711 participants
Moderate

Benralizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Rate ratio 0.88 [0.78, 1]
2 studies · 1512 participants
Moderate

Benralizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Rate ratio 1.02 [0.87, 1.2]
2 studies · 720 participants
Moderate